A premium vector and transposon platform delivering higher yields and faster cell line development in CHO and HEK systems.
2G UNic is trusted by leading biotechnology companies and CDMOs worldwide to deliver higher-yield production and improved manufacturing performance across biologics, biosimilars and advanced therapies.
Proven across monoclonal antibodies, biosimilars, and complex or difficult-to-express biologics
2G UNic enables higher, more stable protein expression across CHO and HEK systems, supporting monoclonal antibodies, biosimilars, and complex biologics, without requiring changes to existing workflows.
By improving both transcription and translation efficiency, the platform delivers stronger expression, more reliable cell lines, and faster progression from transfection to production.
No Data Found
Representative data showing up to 10 g/L titers achieved with 2G UNic in CHO and HEK expression systems.
Vector architecture engineered to maximise transcription and translation efficiency
Semi-targeted transposon integration improves consistency compared to random methods
No changes required to host systems, selection strategies, or development processes
Used in molecules progressing to late-stage development and trusted by leading CDMOs
Together, these mechanisms amplify protein synthesis at every stage, producing more mRNA, more protein, and ultimately higher titers per integrated gene copy in both CHO and HEK systems.
2G UNic vector technology integrates seamlessly with leading transposon systems, including 2G UNic Transposon, PiggyBac, Sleeping Beauty, and others, enabling flexible, high-yield cell-line development and manufacturing workflows.
When paired with major transposon platforms, 2G UNic vector technology consistently increases expression levels and accelerates cell-line development in both CHO and HEK systems.
No Data Found
2G UNic improves transcription and translation at the vector level.
When combined with transposon-based integration, this translates directly into:
The platform can be used with existing transposon systems or as part of the full 2G UNic Transposon solution, depending on your development strategy.
2G UNic vector technology is adaptable across multiple expression systems.
Beyond its proven performance in mammalian hosts such as CHO and HEK, the platform has also been successfully implemented in yeast (Pichia pastoris / Komagataella phaffii) for efficient production of recombinant proteins, enzymes, and vaccine antigens.
The same principles of transcriptional control and translational enhancement that drive mammalian performance can also support productivity in microbial systems.
2G UNic integrates directly into standard CHO and HEK cell-line development workflows without requiring proprietary host systems or extensive revalidation.
It is compatible with common selection markers, vector backbones, and transposon systems, enabling rapid evaluation and scale-up within existing platforms. Applicable across monoclonal antibodies, biosimilars, and complex biologics.
CDMOs and biopharma developers can adopt 2G UNic as:
Flexible adoption pathway
3–10× titer boost
30 – 50% shorter CLD timelines
Expression maintained
We use cookies to improve your experience on our site. By using our site, you consent to cookies.
Manage your cookie preferences below:
Essential cookies enable basic functions and are necessary for the proper function of the website.
These cookies are needed for adding comments on this website.